# Relative Drug Exposures Of Two Formulations of PF-02341066

> **NCT00939731** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** PF-02341066
- **DRUG:** PF-02341066

## Key facts

- **NCT ID:** NCT00939731
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2011-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00939731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00939731, "Relative Drug Exposures Of Two Formulations of PF-02341066". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00939731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*